American Chemical Society--238th National Meeting & Exposition. Developments in medicinal chemistry: part 1. 16-20 August 2009, Washington DC, USA.
The 238th National Meeting and Exposition of the American Chemical Society, held in Washington DC, included topics covering new compounds and developments in the field of medicinal chemistry. This conference report highlights selected presentations on a novel KV1.5 blocker, a state-dependent CaV2.2 antagonist, therapeutic uses of macrocycles, a novel P2X7 antagonist, developments using the StaR technology platform, the optimization of a neuropeptide S receptor antagonist, and type 1 glycine transport modulators. Investigational drugs discussed include WYE-160020 (Wyeth), Trox-1 (Neuromed Pharmaceuticals Inc), ulimorelin (Tranzyme Pharma Inc), E-32224 (Ensemble Discovery Corp) and PF-03463275 (Pfizer Inc); the discontinued compound AZD-9056 is also highlighted.
Gater
Deborah
D
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. deborah.gater@thomsonreuters.com
Macauley
Donald
D
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D004219:District of Columbia; D055808:Drug Discovery / Q000639:trends*; D015507:Drugs, Investigational / Q000008:administration & dosage; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D012955:Societies, Medical / Q000639:trends*; D012958:Societies, Scientific / Q000639:trends*; D014481:United States
D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations